Related Experiment Videos
Ranitidine reduces phosphate binding in dialysis patients receiving calcium carbonate
C C Tan1, P N Harden, R S Rodger
1Renal Unit and Department of Biochemistry, Western Infirmary, Glasgow, UK.
Summary
Ranitidine significantly increased serum phosphate levels in dialysis patients, indicating it impairs the phosphate-binding efficacy of calcium carbonate. This finding is crucial for managing hyperphosphatemia in renal failure.
Area of Science:
- Nephrology
- Clinical Pharmacology
Background:
- Previous studies indicated ranitidine reduces phosphate binding with aluminum hydroxide.
- The mechanism may involve increased intragastric pH.
Purpose of the Study:
- To investigate ranitidine's effect on calcium carbonate phosphate binding in dialysis patients.
- To assess the impact of ranitidine on mineral metabolism markers.
Main Methods:
- A double-blind, crossover trial involving 15 dialysis patients.
- Patients received either ranitidine (300 mg) or placebo before breakfast for two 4-week periods.
- Serum phosphate, calcium, albumin, alkaline phosphatase, and parathyroid hormone (PTH) levels were monitored.
Main Results:
- Serum phosphate levels were significantly higher with ranitidine (1.78 mmol/l) compared to placebo (1.59 mmol/l).
- No significant differences were observed in serum calcium, albumin, alkaline phosphatase, or PTH levels between treatments.
Conclusions:
- Ranitidine adversely affects the phosphate-binding capacity of calcium carbonate.
- This interaction can lead to elevated serum phosphate in patients with renal failure.